Catalent pushes into gene therapy with $1.2 billion buyout of Paragon Bioservices

Catalent Inc said on Monday it would buy privately held gene therapy-focused Paragon Bioservices Inc in an all-cash deal for $1.2 billion, helping the drug developer expand its capabilities to make specialized and costly treatments.